Britain’s drug regulatory authority granted approval Thursday for a new oral weight-loss medication from Novo Nordisk, providing patients with an injection-free option for treating obesity while strengthening the Danish pharmaceutical company’s competitive position ahead of U.S. competitor Eli Lilly.
This regulatory clearance offers a more user-friendly treatment choice for over 10 million residents of England as pharmaceutical companies compete to broaden the reach of these medications, which have revolutionized the weight-loss treatment market and transformed the drug industry landscape.
The Medicines and Healthcare products Regulatory Agency has cleared the Wegovy pill for adult patients dealing with obesity who maintain a body mass index of 30 or higher, as well as individuals with BMI readings from 27 to 30 who also have at least one obesity-related health condition.
Following this regulatory clearance, Britain’s National Institute for Health and Care Excellence will conduct its own evaluation before the medication becomes accessible through the NHS healthcare system.
In the interim, patients may obtain the pill from private healthcare providers. Novo anticipates the medication will become accessible through private prescriptions in the coming weeks.
Danielle Brightman, clinical director at digital healthcare platform Numan, stated that clearing oral medication means “better access for more people battling obesity”.
Current NHS England data indicates that obesity impacts approximately 30% of adults in England, representing roughly 13 million to 14 million individuals.
The Novo pill features semaglutide, the identical active compound found in the company’s highly successful injectable medications Wegovy for weight management and Ozempic for diabetes treatment.
